Needle Tract Implantation after Percutaneous Interventional Procedures in Hepatocellular Carcinomas: Lessons Learned from a 10-year Experience

Chang, Sun O; Kim, Seong Hyun; Lim, Hyo Keun; Kim, Seung Hoon; Lee, Won Jae; Choi, Dongil; Kim, Young Sun; Rhim, Hyunchul

doi:10.3348/kjr.2008.9.3.268

Cited by 55 publications

(46 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, three cryoprobes were inserted sequentially, and one of them was inserted into the tumor with an interposition of the normal hepatic parenchyma at a short distance, although we could not judge which needle tract was responsible for the seeding tumor because of the proximity of the three hepatic insertion sites. The possible mechanisms of tumor seeding are as follows: adherence of viable cancer cells to the needle, blood reflux along the tract, or cancer cells being forced into the tract due to increased intratumoral pressure [7]. Tumor seeding typically occurs along the needle tract, but in a few cases, occurred at a distant location in the peritoneal cavity [3,6].…”

Section: Discussionmentioning

confidence: 99%

“…Tumor seeding typically occurs along the needle tract, but in a few cases, occurred at a distant location in the peritoneal cavity [3,6]. Various risk factors of tumor seeding after percutaneous hepatic ablation treatments have been reported, including subcapsular location of the tumor, direct subcapsular needle insertion, number of sessions, tumor differentiation, a large needle bore, and tumor size and biopsy prior to ablation [6,7]. Wang et al showed, via multivariate analysis, that the only significant risk factor for seeding was direct subcapsular needle insertion in the cryoablation of a hepatic tumor [6].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Needle Tract Seeding after Percutaneous Cryoablation of a Metastatic Hepatic Tumor from Renal Cell Carcinoma: A Case Report

Gobara

Kobayashi

Iguchi

et al. 2017

Interventional Radiology

View full text Add to dashboard Cite

A 61-year-old woman with renal cancer underwent percutaneous cryoablation (PCA) for a metastatic hepatic tumor. Because the tumor was subcapsular and 3.6 cm in diameter, we performed transcatheter arterial embolization before PCA. Three cryoprobes were placed in triangular configuration; one inserted with an interposition of the normal hepatic parenchyma at a short distance. Computed tomography (CT) 2 days after PCA showed no contrast enhancement in the ablation zone with adequate ablation margins. CT after 2 months showed small enhancing foci on the hepatic surface. Tumors were located along previously inserted needle track, confirming diagnosis of needle tract seeding. A laparoscopically extirpated specimen revealed clear cell carcinoma, comparable to metastasis from renal cancer. CT after 6 months found additional seeding tumors, and systemic therapy was administered.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Needle Tract Seeding after Percutaneous Cryoablation of a Metastatic Hepatic Tumor from Renal Cell Carcinoma: A Case Report

Gobara

Kobayashi

Iguchi

et al. 2017

Interventional Radiology

View full text Add to dashboard Cite

show abstract

“…The failure of image guided percutaneous biopsy is observed in 3%-16% of cases, which may arise with inadequate sampling, and raises risks of false negative diagnosis, particularly in well differentiated HCC. The chances of success with repeat biopsy is relatively low when the deficiency is limited by characteristics of the lesions, such as areas of necrosis in large nodules or well differentiated cellular areas in small sized HCC, and increases the risk of bleeding and tumor seeding (42).…”

Section: The Role Of Liver Biopsymentioning

confidence: 99%

MRI of hepatocellular carcinoma: an update of current practices

Arif-Tiwari

Kalb

Chundru

et al. 2014

Diagn Interv Radiol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, and liver transplantation is the optimal treatment for selected patients with HCC and chronic liver disease (CLD). Accurate selection of patients for transplantation is essential to maximize patient outcomes and ensure optimized allocation of donor organs. Magnetic resonance imaging (MRI) is a powerful tool for the detection, characterization, and staging of HCC. In patients with CLD, the MRI findings of an arterial-enhancing mass with subsequent washout and enhancing capsule on delayed interstitial phase images are diagnostic for HCC. Major organizations with oversight for organ donor distribution, such as The Organ Procurement and Transplantation Network (OPTN), accept an imaging diagnosis of HCC, no longer requiring tissue biopsy. In patients that are awaiting transplantation, or are not candidates for liver transplantation, localized therapies such as transarterial chemoembolization and radiofrequency ablation may be offered. MRI can be used to monitor treatment response. The purpose of this review article is to describe the role of imaging methods in the diagnosis, staging, and follow-up of HCC, with particular emphasis on established and evolving MRI techniques employing nonspecific gadolinium chelates, hepatobiliary contrast agents, and diffusion weighted imaging. We also briefly review the recently developed Liver Imaging Reporting and Data System (LI-RADS) formulating a standardized terminology and reporting structure for evaluation of lesions detected in patients with CLD.H epatocellular carcinoma (HCC) is a major worldwide health concern; it is the sixth most common cancer and third leading cause of overall cancer-related mortality. HCC frequently presents as a rapidly growing tumor and has historically been associated with poor prognosis and outcomes. However, tumor screening protocols in high risk patients can lead to an earlier detection of treatable disease. Screening for HCC has resulted in significant improvements in the one-year cause-specific survival rates for new patients (1), and this is directly attributed to improved survival through the detection of early stage tumor.The five-year cumulative risk of HCC ranges from 4%-30% in patients with chronic liver disease (CLD) and cirrhosis (2-3). Multiple therapeutic strategies are available for the treatment of HCC, including medical therapy, percutaneous tumor ablation, transarterial embolic therapy, surgical resection, and liver transplantation. Of all the available methods, liver transplantation is the most effective treatment for early HCC because this method removes not only the tumor but also the entire cirrhotic liver, which is at an increased risk for developing metachronous tumors. The effectiveness of liver transplantation depends upon detecting early stage disease within specific criteria. A seminal paper by Mazzaferro et al. (4), published in 1996, established the "Milan criteria" as the most widely used guidelines for transplant eligibility. The Mila...

show abstract

“…The incidence of seeding has been the subject of a number of studies, with reported incidence varying widely from 0 to 11%. [53][54][55][56][57][58] A literature review performed by Stigliano et al 55 concluded that the overall mean risk of seeding is 1.73%, based on results from 2242 patients. The exact incidence of needle tract seeding is difficult to accurately determine, as there have been only case reports and small retrospective studies.…”

Section: Post-fine-needle Aspiration Soft-tissue Metastasesmentioning

confidence: 99%

Cirrhosis-related musculoskeletal disease: radiological review

Arora¹,

Rajesh²,

Bansal³

et al. 2016

BJR

View full text Add to dashboard Cite

Musculoskeletal problems in patients with liver disease are common; however, they are not so well described in the literature. Therefore, there is a need to collate information on these disorders, as their incidence is on a constant rise and some of these pathologies can severely debilitate the patient's quality of life. These disorders are parietal wall varices with or without bleeding, spontaneous intramuscular haematoma (e.g. rectus sheath), abdominal wall hernia, anasarca, hepatic osteodystrophy, septic arthritis, osteomyelitis, necrotizing fasciitis, osseous metastases from hepatocellular carcinoma etc. While portal hypertension plays a key role in disorders, in others, dysregulation of the coagulation system or a compromised immune system are responsible. Imaging plays an essential role in the assessment of these complications and awareness of these musculoskeletal manifestations is vital for establishing a timely diagnosis and planning of appropriate therapy, as these disorders can significantly impact the morbidity and mortality and also influence candidacy for liver transplantation. We herein comprehensively appraise various musculoskeletal complications associated with chronic liver disease/liver cirrhosis especially from an imaging perspective which, to the best of our knowledge, have not been collectively described in English literature.

show abstract

Needle Tract Implantation after Percutaneous Interventional Procedures in Hepatocellular Carcinomas: Lessons Learned from a 10-year Experience

Cited by 55 publications

References 23 publications

Needle Tract Seeding after Percutaneous Cryoablation of a Metastatic Hepatic Tumor from Renal Cell Carcinoma: A Case Report

Needle Tract Seeding after Percutaneous Cryoablation of a Metastatic Hepatic Tumor from Renal Cell Carcinoma: A Case Report

MRI of hepatocellular carcinoma: an update of current practices

Cirrhosis-related musculoskeletal disease: radiological review

Contact Info

Product

Resources

About